Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOM: Denosumab in Postmenopausal Osteoporosis
NCT00089791Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2004
- Primary completion
- Jun 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing Placebo with Denosumab (2 arms). Primary endpoint: Incidence of New Vertebral Fractures at 36 months. Started Aug 2004; status: completed.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00089791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089791.